Celldex Therapeutics, Inc. is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Hampton, NJ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2 million and a loss of $259 million (its filed statements).
Pre-revenue companyIn Vitro & In Vivo Diagnostic SubstancesHampton, NJfilings since 19958 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2835), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.0 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.3 out of ten, present 6.0 out of ten, future 5.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 4.2 out of ten. 2 warning events since 2017; the latest 2018-11-27. 42nd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.2 out of ten. -15.2% a year over 10 filed years; profitable in 0 of 7. 22nd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.2 out of ten. CrossAssetData estimate 4.2/10, confidence 35 of 100 (one part). 42nd percentile among 18 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.8 out of ten. ROE -49%: lost 49¢ per shareholder dollar. Leverage 10%: owes 10¢ per asset dollar. 58th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 1.5 out of ten. bottom 15% of 17 in its family; net margin -16748%. 15th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 9.4 out of ten. top 6% of 15 in its family for leadership; chief executive since 2009. 94th percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 6.2 out of ten. top 38% of 16 in its family for room to expand. 62nd percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.3 out of ten. top 36% of 17 in its family for growth drivers. 64th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 1.2 out of ten. bottom 12% of 16 in its family for expectations against reality. 12th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-25 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-07. Filings on record since 1995. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Grant 94%, Service 6%. As tagged in its annual report (Form 10-K, filed 2026-02-25).
Who runs it
Marucci, Anthony S (PRESIDENT & CEO); Martin, Samuel Bates (SVP AND CFO); Lawver, Teri L (SVP & Chief Commercial Officer); Young, Diane C. (SVP, CHIEF MEDICAL OFFICER); Cavanaugh, Sarah (SVP OF CORP AFFAIRS & ADMIN.); Crowley, Elizabeth (SR. VP & CPDO); Heath-Chiozzi, Margo (SVP OF REGULATORY AFFAIRS); Jimenez, Freddy A. (SVP & GENERAL COUNSEL); Keler, Tibor (EXECUTIVE VP & CSO); Pepin, Ronald (SR. VP & CBO); and 9 more. 19 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.